ALFA Filings
Every announcement, straight from the exchange
Announcement type
Time
5 announcements
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.